ArticleVaccines2022
Which Type of the Promising COVID-19 Vaccines Produces Minimal Adverse Effects? A Retrospective Cross-Sectional Study.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Safety and efficiency of COVID-19 vaccine in North Africa.Human vaccines & immunotherapeutics · 2024Article
- Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination.Current microbiology · 2023Article
- Side effects of COVID-19 vaccines in the middle eastern population.Frontiers in immunology · 2023Review
- Web-Based Reporting of Post-Vaccination Symptoms for Inactivated COVID-19 Vaccines in Jordan: A Cross-Sectional Study.Vaccines · 2022Article
- SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study.Vaccines · 2022Article
- Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers.Frontiers in public health · 2022Article
- COVID-19 vaccination, do women suffer from more side effects than men? A retrospective cross-sectional study.Pharmacy practiceArticle
- Depression, anxiety and stress after COVID-19 vaccination: A retrospective cross-sectional study among health care providers.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the declaration of Coronavirus-2019 (COVID-19) as a pandemic by the World Health Organization (WHO), it was clear that vaccination is the best way to overcome it. Sinopharm, AstraZeneca and Pfizer were the first vaccines introduced to defeat it. To recognize the short-term adverse effects among Iraqi health care workers (HCWs) after vaccination, the three COVID-19 vaccines that are currently available in Iraq were compared. An online survey was distributed to Iraqi HCWs who had received at least one of the COVID-19 vaccines as part of a retrospective cross-sectional study. Data were statistically analyzed using SPSS. The total number of participants was 843. The majority of the participants (85.9%) were under 39 years old, with 78.8% of them being females. Around 60% of individuals had received the Pfizer vaccine. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had infected 46.7% of the total participants. A total of 628 out of 843 participants experienced adverse effects after receiving the vaccine, accounting for 74.49% of the overall respondents. After receiving the COVID-19 vaccine, the vast majority of respondents who received the three vaccines experienced pain at the injection site (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.